Express Scripts Repatha, Praluent Deals: What It Means

After all the handwringing about whether payers would cover the newly approved proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors Praluent (alirocumab), marketed by Sanofi SA and Regeneron Pharmaceuticals Inc., and Repatha (evolocumab), from Amgen Inc., Express Scripts Holding Co., the largest pharmacy benefit management (PBM) company in the US, said it has sealed deals for both drugs – declaring it has scored discounts on the medicines, which means neither will be excluded from its formulary.